Free Trial
Rami Katkhuda

Rami Katkhuda Analyst Performance

Managing Director, Senior Equity Research Analyst at Lifesci Capital

Rami Katkhuda is a stock analyst at Lifesci Capital in the healthcare sector, covering 12 publicly traded companies. Over the past year, Rami Katkhuda has issued 2 stock ratings, including and buy recommendations. While full access to Rami Katkhuda's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Rami Katkhuda's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 5 Years
Buy Recommendations
84.62% 11 Buy Ratings
Companies Covered
12 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy7.7%1 ratings
Buy76.9%10 ratings
Hold15.4%2 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Rami Katkhuda at Lifesci Capital, the majority (76.9%) have been Buy recommendations, followed by 15.4% Hold and 7.7% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
91.7% of companies on NASDAQ
11 companies
NYSE
8.3% of companies on NYSE
1 company

Rami Katkhuda, an analyst at Lifesci Capital, currently covers 12 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
12 companies
100.0%

Rami Katkhuda of Lifesci Capital specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
8 companies
66.7%
PHARMACEUTICALS
4 companies
33.3%

Rami Katkhuda's Ratings History at Lifesci Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
7/22/2026Initiated Coverage$11.79$40.00Outperform
Veradermics, Incorporated stock logo
MANE
Veradermics
6/16/2026Initiated Coverage$93.79$135.00Outperform
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
9/9/2025Downgrade$47.64$48.00Hold